Our vision is to form a total MRI-guided solution tackling soft tissue imaging where precision and accuracy matter most
With best-in-class robotics, IGAR has a vital role to play in solving this challenge. Our robotic solution can work inside the MRI bore mounted on the MRI table.
The IGAR robotic system has secured a successful 510(k) clearance from the FDA. We've demonstrated IGAR’s safety and efficacy through published clinical studies in breast biopsy.
The IGAR technology platform may be adapted for future products that could move seamlessly across different care environments, such as from an MRI to a standard operating room or into a physician’s office. Its other possible applications include targeting other organs and disease indications, along with therapeutic delivery and device placement.
In the US alone, over 40 million MRI exams occur every year on an estimated 12,000 MRI machines. MRI is primarily used for diagnostic scans, but is not used as the standard of care for guiding treatment in any procedure.
This market gap is being solved by the invention of smaller, portable MRI machines. Cheaper, smaller, more accessible MRI technology–coupled with advances in machine learning and imaging software powered by AI analysis opens up exciting new possibilities for better, more accessible care.
At the same time, our target markets are those where accuracy and precision matter most.
Based on clinical studies published from 2016 to 2021 and our own conversations with physicians, we see possible applications for the IGAR technology platform beyond breast biopsy.
We envision targeting other organs and disease indications, along with therapeutic delivery and device placement.
In the US alone, over 40 million MRI exams occur every year on an estimated 12,000 MRI machines. But demand far exceeds capacity, limiting the clinical disciplines where MRI’s accuracy can be brought to bear.
This market gap is being solved by the invention of smaller, portable MRI machines. Cheaper, smaller, more accessible MRI technology–coupled with advances in machine learning and imaging software powered by AI analysis opens up exciting new possibilities for better, more accessible care.
At the same time, our target markets are those where accuracy and precision matter most.
Based on clinical studies published from 2016 to 2021 and our own converstations with physicians, we see possibile applications for IGAR.
Insight Medbotics is proud to be supported by a group of leading investors, including MDA and the Centre for Surgical Invention & Innovation (CSii).
www.mda.space
Serving the world from its Canadian home and global offices, MDA (TSX:MDA), is an international space mission partner and a robotics, satellite systems and geointelligence pioneer with a 50-year story of firsts on and above the Earth. With 2,000 employees in Canada, the US and the UK, MDA is leading the charge towards viable Moon colonies, enhanced Earth observation, communication in a hyper-connected world, and more. With a track record of making ambitions come true, MDA enables highly skilled people to continually push boundaries, tackle big challenges, and imagine solutions that inspire and endure to change the world for the better, on the ground and in the stars.
www.csii.ca/about-us
In 2009 the Centre for Surgical Invention and Innovation (CSii) was granted $15 million by the Canadian Network Centres of Excellence CECR program to establish a non-for-profit research incubator, to leverage Canadian investment in space technology for use in the development of Image Guided Automated Robotics (IGARTM) and support the research & development of IP generated by researchers in the field of medical robotics and related technologies.
Insight Medbotics is actively developing partnerships with companies in the MRI-compatible AI software or portable/office-based MRI spaces, along with therapy providers who would benefit from targeted, precision delivery.